News & stories

News | May 26, 2023

MSF welcomes World Health Assembly resolution on disease testing

Governments must now implement the resolution and make sure diagnostic tools are widely affordable and accessible

News | Apr 26, 2023

J&J must stop blocking generic versions of lifesaving TB drug

J&J’s patent monopoly continues to keep bedaquiline out of reach.

News | Mar 23, 2023

MSF applauds rejection of J&J attempt to extend TB drug patent

The rejection of the salt form of bedaquiline is welcome news for people with drug-resistant tuberculosis.

News | Mar 22, 2023

World TB Day: More people need access to testing and treatment

MSF calls on governments and donors to speed up access to new, improved treatment for drug-resistant tuberculosis.

News | Dec 21, 2022

MSF trial finds better treatment for people with TB

Results published in the New England Journal of Medicine today show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of patients

News | Dec 15, 2022

WHO recommends TB regimen found effective by MSF clinical trial

News | Nov 08, 2022

MSF: Opportunity to increase access to newer, safer TB drugs is at risk

With newer TB drugs set to go off patent in 2023, drugmakers J&J, Otsuka, and TB Alliance must remove additional barriers that block more affordable versions from entering the market.

News | Oct 27, 2022

With cases on the rise, MSF repeats call for more affordable DR-TB treatment

The price of a full DR-TB treatment course should be no more than $500 per person.

News | Sep 19, 2022

MSF: Donor countries must increase funding pledges during Global Fund replenishment conference

News | Sep 15, 2022

MSF: Cepheid’s production delays of critical tuberculosis test will cost lives